Evidence map›Paper›PMID 31564018›Full record

Observational studyJournal of thrombosis and thrombolysis2020

Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.

Markus Gulilat, Denise Keller, Bradley Linton, A Demetri Pananos, Daniel Lizotte, George K Dresser, Jeffrey Alfonsi, Rommel G Tirona, Richard B Kim, Ute I Schwarz

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Drug design, development and therapy · 2023
    Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Pharmacogenomics Informs Cardiovascular Pharmacotherapy.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Markus GulilatDivision of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
Denise KellerDivision of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
Bradley LintonDivision of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
A Demetri PananosDepartment of Epidemiology and Biostatistics, Western University, London, ON, Canada.
Daniel LizotteDepartment of Epidemiology and Biostatistics, Western University, London, ON, Canada.
George K DresserDivision of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
Jeffrey AlfonsiDivision of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
Rommel G TironaDivision of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
Richard B KimDivision of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
Ute I SchwarzDivision of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada. ute.schwarz@lhsc.on.ca.ORCID http://orcid.org/0000-0003-1569-1580
Western University · CA

Funding

CIHR DSEN-PREVENTCIHR FRN-117588CIHR PCG-154864CIHR Personalized Health Catalyst GrantOntario Ministry of Research, Innovation and Science ORF-RE08-063
6 · The paper itself

Abstract

Factor Xa-inhibitor apixaban is an oral anticoagulant prescribed in atrial fibrillation (AF) for stroke prevention. Its pharmacokinetic profile is known to be affected by cytochrome P450 (CYP)3A metabolism, while it is also a substrate of the efflux transporters ATP-binding cassette (ABC)B1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein, BCRP). In this study, we assessed the impact of interacting medication and pharmacogenetic variation to better explain apixaban concentration differences among 358 Caucasian AF patients. Genotyping (ABCG2, ABCB1, CYP3A4*22, CYP3A5*3) was performed by TaqMan assays, and apixaban quantified by mass spectrometry. The typical patient was on average 77.2 years old, 85.5 kg, and had a serum creatinine of 103.1 µmol/L. Concomitant amiodarone, an antiarrhythmic agent and moderate CYP3A/ABCB1 inhibitor, the impaired-function variant ABCG2 c.421C > A, and sex predicted higher apixaban concentrations when controlling for age, weight and serum creatinine (multivariate regression; R

Indexed as

AgedAged, 80 and overATP Binding Cassette Transporter, Subfamily G, Member 2Atrial FibrillationCytochrome P-450 CYP3ADrug InteractionsFactor Xa InhibitorsFemaleHumansMaleMiddle AgedNeoplasm ProteinsPharmacogeneticsProspective StudiesPyrazolesPyridonesABCG2 protein, humanapixabanATP Binding Cassette Transporter, Subfamily G, Member 2CYP3A4 protein, humanCytochrome P-450 CYP3AFactor Xa InhibitorsNeoplasm ProteinsPyrazolesPyridonesApixabanAtrial fibrillationBreast cancer resistance protein genotypeConcomitant amiodaronePharmacokinetics

Identifiers

PMID31564018
OpenAlexW2975999253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.